Elscint numbers jump on CT sales growth
The strong performance of Elscint's CT product line paced thecompany to improved financial results for its second quarter (end-June).The Haifa vendor reported revenues for the quarter increasing21% to $66.1 million, compared to $54.7 million in the same
The strong performance of Elscint's CT product line paced thecompany to improved financial results for its second quarter (end-June).The Haifa vendor reported revenues for the quarter increasing21% to $66.1 million, compared to $54.7 million in the same perioda year ago.
The company's net income was up as well, to $4.9 million inthe most recent quarter, compared to $2.7 million in the secondquarter of 1995. Net income for the second quarter of 1995 includes$1.6 million from settlement of a patent dispute with Sopha Medical(SCAN 7/28/93).
Dr. Thomas Spackman, president of Elscint's U.S. subsidiary,said the numbers were paced by strong growth in internationalmarkets, as well as a good performance in CT both in the U.S.and globally.
"There has been a real resurgence in some of the markets,in Eastern and Western Europe, and to some extent North and SouthAmerica," Spackman said. "There is growth in rest ofthe world, and the U.S. is hanging on."
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
